Effects of solvents on skin permeation of formoterol fumarate

Biological and Pharmaceutical Bulletin

Volumn 29, Issue 1, 2006, Pages 146-149

  Kakubari, Ikuhiro ^a   Nakamura, Noriko ^a   Takayasu, Toshiyuki ^a   Yamauchi, Hitoshi ^a   Takayama, Satoshi ^a   Takayama, Kozo ^b  

^a DAIICHI SANKYO CO   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

Formoterol; l menthol; N methyl 2 pyrrolidone; Skin permeation; Solvent

Indexed keywords

2 PYRROLIDONE DERIVATIVE; ALCOHOL DERIVATIVE; CINEOLE; FATTY ACID; FORMOTEROL FUMARATE; MYRISTIC ACID ISOPROPYL ESTER; TERPENE DERIVATIVE;

ANIMAL TISSUE; ARTICLE; COMPARATIVE STUDY; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; MALE; NONHUMAN; RAT; SKIN PERMEABILITY; SOLVENT EFFECT; STATISTICAL SIGNIFICANCE;

ADMINISTRATION, CUTANEOUS; ANIMALS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DRUG SYNERGISM; ETHANOLAMINES; EXCIPIENTS; MALE; PERMEABILITY; RATS; RATS, WISTAR; SKIN ABSORPTION; SOLVENTS;

EID: 29844448442     PISSN: 09186158     EISSN: 13475215     Source Type: Journal    
DOI: 10.1248/bpb.29.146     Document Type: Article

References (20)

1. Green P. G., J. Controlled Release, 41, 33-48 (1996).
2. Bommannan D., Okuyama H., Stauffer P., Guy R. H., Pharm. Res., 9, 559-564 (1992).
3. Bommannan D., Menon G. K., Okuyama H., Elias P. M., Guy R. H., Pharm. Res., 9, 1043-1047 (1992).
4. Okabe H., Takayama K., Ogura A., Nagai T., Drug Design Delivery, 4, 313-321 (1989).
5. Okabe H., Obata Y., Takayama K., Nagai T., Drug Design Delivery, 6, 229-238 (1990).
6. Barry B. W., Southwell D., Woodford R., J. Invest. Dermatol., 82, 49-52 (1984).
7. Woodford R., Barry B. W., J. Toxicol.-Cut. Ocular Toxicol., 5, 167-177 (1986).
8. Cooper E. R., J. Pharm. Sci., 73, 1153-1156 (1984).
9. Sato K., Sugibayashi K., Morimoto Y., Int. J. Pharm., 43, 31-40 (1988).
10. Bartow R. A., Brogden R. N., Drugs, 55, 303-322 (1998).
11. Faulds D., Hollingshead L. M., Goa K. L., Drugs, 42, 115-137 (1991).
12. Akhter S. A., Barry B. W., J. Pharm. Pharmacol., 37, 27-37 (1985).
13. Obata Y., Takayama K., Okabe H., Nagai T., Drug Design Delivery, 6, 319-328 (1990).
14. Ogiso T., Iwaki M., Paku T., J. Pharm. Sci., 84, 482-488 (1995).
15. Manabe E., Tanaka S., Sugibayashi K., Morimoto Y., Yakuzaigaku (J. Pharm. Sci. Technol., Jpn.), 58, 10-16 (1998).
16. Hoelgaard A., Møllgaard B., Baker E., Int. J. Pharm., 43, 233-240 (1988).
17. Seki T., Kawaguchi T., Juni K., Sugibayashi K., Morimoto Y., J. Controlled Release, 17, 41-47 (1991).
18. Morimoto Y., Sugibayashi K., Kobayashi D., Shoji H., Yamazaki J., Kimura M., Int. J. Pharm., 91, 9-14 (1993).
19. Karino A., Hayashi M., Horie T., Awazu S., Minami H., Hanano M., J. Pharmacobio-Dyn., 5, 410-417 (1982).
20. Lashmar U. T., Hadgraft J., Thomas N., J. Pharm. Pharmacol., 41, 118-122 (1989).